Group B Streptococcus GBS Diagnosis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Group B Streptococcus (GBS) Diagnosis Market is segmented By Diagnostic Method (Culture Test, PCR Testing, Serological Testing), By Treatment Type (Antibiotics (Penicillin, Ampicillin), Vaccines, Probiotics), By End User(Hospitals, Clinics, Diagnostic Laboratories), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Group B Streptococcus GBS Diagnosis Market Size
Market Size in USD
CAGR5.4%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5.4% |
| Market Concentration | Medium |
| Major Players | Pfizer Inc., Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Sanofi |
please let us know !
Group B Streptococcus GBS Diagnosis Market Analysis
The group B streptococcus (GBS) diagnosis market is estimated to be valued at USD 1.58 billion in 2024 and is expected to reach USD 2.28 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. Rapid advancements in screening technologies and growing awareness about GBS infections during pregnancy are expected to drive the group B streptococcus (GBS) diagnosis market during the forecast period.